Celldex Therapeutics, Inc.
CLDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000744218
No open-market purchases or sales by Celldex Therapeutics, Inc. insiders were filed in the last 90 days; 253 institutions reported holding it in 13F filings for Q2 2026, worth $3.16B in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Celldex Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 184
- +3 vs. Q2 2025
- Shares held
- 70.7M
- −1.58M (−2.2%) vs. Q2 2025
- Total value
- $1.83B
- +$350.6M (+23.7%) vs. Q2 2025
- New holders
- 29
- 60 more added
- Sold out
- 26
- 57 more reduced
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLDX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 253 | $3.16B |
| Q1 2026 | 229 | $2.31B |
| Q4 2025 | 187 | $1.99B |
| Q3 2025 | 184 | $1.83B |
| Q2 2025 | 182 | $1.48B |
| Q1 2025 | 171 | $1.34B |
| Q4 2024 | 174 | $1.86B |
| Q3 2024 | 176 | $2.44B |
| Q2 2024 | 183 | $2.58B |
| Q1 2024 | 197 | $2.91B |
| Q4 2023 | 164 | $2.42B |
| Q3 2023 | 144 | $1.39B |
| Q2 2023 | 150 | $1.70B |
| Q1 2023 | 161 | $1.78B |
| Q4 2022 | 168 | $2.17B |
| Q3 2022 | 160 | $1.39B |
| Q2 2022 | 158 | $1.30B |
| Q1 2022 | 169 | $1.69B |
| Q4 2021 | 181 | $1.79B |
| Q3 2021 | 161 | $2.33B |
| Q2 2021 | 132 | $1.19B |
| Q1 2021 | 115 | $709.5M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Celldex Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −19,146−100.0% | Sold out |
| Sender Co & Partners, Inc. | 0 | $0 | 0.00% | −15,593−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −11,656−100.0% | Sold out |
| Headlands Technologies LLC | 0 | $0 | 0.00% | −6,119−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −566−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −538−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −281−100.0% | Sold out |
| Close Asset Management Ltd | 0 | $0 | 0.00% | −133−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −78−100.0% | Sold out |
| Fortitude Family Office, LLC | 0 | $0 | 0.00% | −26−100.0% | Sold out |
| First Horizon Advisors, Inc. | – | – | – | – | Not filed |